P53 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT DIAGNOSIS AND FOLLOWING TREATMENT WITH AZACITIDINE

被引：0
|
作者：
Maung, S. [1 ]
Strahan, N. [1 ]
Desmond, R. [1 ]
McHugh, J. [1 ]
Burke, C. [1 ]
O'Loughlin, J. [2 ]
Jeffers, M. [2 ]
Enright, H. [1 ]
机构：
[1] Tallaght Hosp, Trinity Coll, Sch Med, Haematol, Dublin, Ireland
[2] Tallaght Hosp, Trinity Coll, Sch Med, Cellular Pathol, Dublin, Ireland
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1225
引用
收藏
页码：491 / 491
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ritchie, Ellen K.
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 165 - 173
  • [22] Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin J.
    Odenike, Olatoyosi
    Watson, Anne-Marie
    Krishnadasan, Ravi
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Hogdal, Leah
    Zhou, Ying
    Hoffman, David
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [23] Oral Azacitidine in Patients With Myelodysplastic Syndrome
    Shibusawa, Motoharu
    Kidoguchi, Keisuke
    Tanimoto, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3091 - +
  • [24] Determination of p53 genetic polymorphisms in myelodysplastic syndrome cases
    Vatansever, B.
    Aygunes, D.
    Kaymaz, B.
    Alp, G.
    Sahin, F.
    Saydam, G.
    Kosova, B.
    LEUKEMIA RESEARCH, 2018, 73 : S29 - S30
  • [25] P53 mutation in advanced stage of primary myelodysplastic syndrome
    Tang, JL
    Tien, HF
    Lin, MT
    Chen, PJ
    Chen, YC
    ANTICANCER RESEARCH, 1998, 18 (5B) : 3757 - 3761
  • [26] Mutations of the p53 gene in myelodysplastic syndrome and overt leukaemia
    Mori, N
    Hidai, H
    Yokota, J
    Okada, M
    Motoji, T
    Oshimi, K
    Mizoguchi, H
    LEUKEMIA RESEARCH, 1995, 19 (11) : 869 - 875
  • [27] P53 AND PUMA EXPRESSIONS IN BONE MARROW BIOPSIES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
    Bektas, O.
    Uner, A.
    Buyukasik, Y.
    Uz, B.
    Eliacik, E.
    Isik, A.
    Haznedaroglu, I.
    Goker, H.
    Demiroglu, H.
    Aksu, S.
    Ozcebe, O.
    Sayinalp, N.
    HAEMATOLOGICA, 2012, 97 : 369 - 369
  • [28] ANALYSIS OF P53 EXPRESSION BY IMMUNOHISTOCHEMISTRY AS AN ADDITIONAL PROGNOSTIC TOOL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Maung, S. W.
    Strahan, N.
    O'Dowd, S.
    O'Loughlin, J.
    Desmond, R.
    McHugh, J.
    Jeffers, M.
    Enright, H.
    HAEMATOLOGICA, 2016, 101 : 502 - 503
  • [29] Low Vitamin D Levels Are Associated with Inferior Survival Following Azacitidine Treatment in Patients with Myelodysplastic Syndrome
    Radujkovic, Aleksandar
    Schnitzler, Paul
    Ho, Anthony D.
    Dreger, Peter
    Luft, Thomas
    BLOOD, 2015, 126 (23)
  • [30] Relationship of p21 Expression and p53 Mutation Status in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Eskandari, Mohammad
    Goel, Swati
    Verma, Amit
    Albanese, Joseph
    Wang, Yanhua
    MODERN PATHOLOGY, 2017, 30 : 347A - 347A
12345